News

Antibodies that are circulating in the blood of patients who’ve recovered from COVID-19 may serve as the key to developing an effective vaccine against the virus.

The study seeks to evaluate shared data from wearable users as part of a program to improve detection and containment of infectious disease outbreaks.

Ongoing studies reveal important information about how the virus spreads and infects the body, and point to different approaches for potential vaccines and medicines.

Calibr scientists work to repurpose existing drugs against novel coronavirus.

Deep within the brain, alcohol dependence creates a hypersensitivity to stress that lasts long after drinking has stopped.

Putting all the world’s life sciece knowledge into a single open-access repository would turbo-charge bioscience research, says a team of bioinformatics experts led by scientists at Scripps Research.

By analyzing public genome sequence data from the virus that causes COVID-19, the research team found no evidence that the pathogen was made in a laboratory or otherwise engineered.

Molecules needed for energy production in cells apparently underwent a radical change during early animal evolution so they could continue to function despite a relatively high mutation rate.

The discovery of an insulin “decoy” molecule from the lab of Matthew Gill, PhD, in Florida shakes up understanding of insulin signaling, with implications for diabetes, longevity and aging research.  

A team at Scripps Research in Florida has developed a mouse model of a known cause of autism spectrum disorder, a mutation in the gene PTEN, that leads the brain to develop to an abnormal scale, with autism-like behaviors resulting. Restoring one of PTEN’s key activities in that mouse model led to a reversal of some cell overgrowth, offering a potential therapeutic target.   

In a study with implications for the future of drug discovery, Scripps Research scientists showed they were able to turn simple chemicals into unique 3-D structures resembling those found in nature.

The rating acknowledges nonprofit organizations and charities that exceed industry standards in financial health, accountability and transparency.

In a heart study of unprecedented scale, researchers evaluated the resting heart rate of more than 92,000 individuals for over 32 million days using de-identified data from fitness-tracking devices.

Having achieved this regulatory milestone, Calibr can begin clinical trials for its novel cell therapy candidate, which leverages a patient's own immune cells to treat cancer.

Renewed support from the Bill & Melinda Gates Foundation to accelerate research by Calibr, the drug development division of Scripps Research.

The clinical-stage biopharmaceutical company BlackThorn Therapeutics, a spin-off from Scripps Research, has begun patient enrollment for a phase 2 clinical trial to evaluate the impact of its lead drug candidate in individuals with major depressive disorder.

A professor and associate dean, Havran pursued groundbreaking immunology research that revealed key mechanisms of wound healing.

An abundance of microRNA-21 predicts lower survival in people with hard-to-treat “triple-negative” breast cancer. An innovative compound from Disney Lab awakened those cancer cells’ self-destruct system, killing the cancer cells and stopping their spread in a mouse model, while leaving healthy cells untouched.

Alda, the Emmy Award-winning actor, director and writer who has become a leading advocate for effective science communication, has partnered with Scripps Research to bring immersive communication training to scientists.

By analyzing millions of data points from wearable devices, Scripps Research scientists were able to significantly improve statewide predictions of flu epidemics.

Under a two-year contract and funding agreement, Calibr will screen its vast library of drug molecules for compounds that work against a rare but vexing family of bacteria.

Why do we remember some things for our entire lives but quickly forget others? The brain is constantly deciding which events are important enough for long-term storage.  A new study from the lab of neuroscientist Ron Davis, PhD, sheds light on one element of that process.

Mitochondrial damage is increasingly recognized as a major factor for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS. A new screening platform has identified a set of drug-like compounds that may powerfully protect mitochondria.